- Home
- SF vs PEN Comparison
SF vs PEN Comparison
Compare SF & PEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SF
- PEN
- Stock Information
- Founded
- SF 1890
- PEN 2004
- Country
- SF United States
- PEN United States
- Employees
- SF N/A
- PEN N/A
- Industry
- SF Investment Bankers/Brokers/Service
- PEN Medical/Dental Instruments
- Sector
- SF Finance
- PEN Health Care
- Exchange
- SF Nasdaq
- PEN Nasdaq
- Market Cap
- SF 11.4B
- PEN 9.7B
- IPO Year
- SF N/A
- PEN 2015
- Fundamental
- Price
- SF $125.43
- PEN $281.69
- Analyst Decision
- SF Buy
- PEN Strong Buy
- Analyst Count
- SF 8
- PEN 16
- Target Price
- SF $126.88
- PEN $307.19
- AVG Volume (30 Days)
- SF 771.8K
- PEN 459.5K
- Earning Date
- SF 10-22-2025
- PEN 11-05-2025
- Dividend Yield
- SF 1.51%
- PEN N/A
- EPS Growth
- SF 2.14
- PEN 367.34
- EPS
- SF 5.66
- PEN 4.14
- Revenue
- SF $5,293,276,000.00
- PEN $1,333,798,000.00
- Revenue This Year
- SF $13.37
- PEN $15.52
- Revenue Next Year
- SF $11.33
- PEN $14.20
- P/E Ratio
- SF $21.54
- PEN $66.42
- Revenue Growth
- SF 11.76
- PEN 14.61
- 52 Week Low
- SF $73.27
- PEN $221.26
- 52 Week High
- SF $123.57
- PEN $310.00
- Technical
- Relative Strength Index (RSI)
- SF 75.77
- PEN 67.71
- Support Level
- SF $116.38
- PEN $225.52
- Resistance Level
- SF $123.57
- PEN $272.00
- Average True Range (ATR)
- SF 2.52
- PEN 9.20
- MACD
- SF 0.64
- PEN 5.41
- Stochastic Oscillator
- SF 97.52
- PEN 97.97
About SF Stifel Financial Corporation
Stifel Financial Corp is a middle-market-focused investment bank that produces more than 90% of its revenue in the United States. Approximately 67% of the company's net revenue is derived from its world-wide wealth management division, which supports over 2,000 financial advisors, with the remainder coming from its institutional securities business. Stifel has a history of being an active acquirer of other financial-services firms.
About PEN Penumbra Inc.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.